Form 4: Corcept Therapeutics CDO Exercises and Sells Shares Under 10b5-1 Plan

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold a portion of the acquired common stock on July 17 and 18, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), engaged in transactions involving company common stock and stock options.
• On July 17, 2025, Guyer exercised options to acquire 4,379 shares of common stock at an exercise price of $21.65 per share.
• Immediately following the exercise on July 17, 2025, Guyer sold 4,379 shares of common stock at a weighted average price of $73.4811 per share, with actual sale prices ranging from $73.40 to $73.74.
• On July 18, 2025, Guyer exercised options to acquire an additional 500 shares of common stock at an exercise price of $21.65 per share.
• Following this exercise on July 18, 2025, Guyer sold 500 shares of common stock at a weighted average price of $73.442 per share, with actual sale prices ranging from $73.40 to $73.47.
• All reported transactions were conducted pursuant to a Rule 10b5-1 plan adopted by Guyer on November 27, 2024.
• After these transactions, Guyer beneficially owns 5,487 shares of common stock directly and 385,021 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's pre-planned under a 10b5-1, which reduces negative implications. The significant profit on exercised options is a positive for the executive, and the retention of substantial options indicates continued alignment with shareholder interests.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 plan, indicating a planned sale rather than a reaction to immediate market conditions.
• The sale prices ($73.4811 and $73.442) are significantly higher than the exercise price ($21.65), indicating a substantial profit for the officer on the exercised shares.
• The officer retains a significant number of stock options (385,021) and common stock (5,487), indicating continued vested interest in the company's performance.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding the company's future performance, focusing solely on insider transactions.

Management Comments

• The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
• Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.47 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• Fully exercisable.

Industry Context

This Form 4 filing details routine insider transactions (option exercise and sale) for a Chief Development Officer at a biotechnology company. Such transactions are common for executives managing their equity compensation and personal finances, especially when conducted under a pre-arranged 10b5-1 plan, which helps mitigate concerns about trading on material non-public information. The specific transactions do not inherently indicate broader industry trends but reflect an executive monetizing vested equity.

Comparison to Industry Standards

• The document is a standard SEC Form 4 filing, reporting insider transactions. The use of a 10b5-1 plan for these transactions aligns with best practices for corporate insiders to manage their stock holdings while adhering to insider trading regulations.
• The exercise of options and subsequent sale of shares is a common practice for executives in the biotechnology and pharmaceutical sectors, similar to those observed at companies like Amgen, Gilead Sciences, or Biogen, where executives frequently manage their equity compensation through similar mechanisms.

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Development Officer, even under a 10b5-1 plan, could be perceived as a slight reduction in insider alignment, though the retained holdings mitigate this. The transactions themselves do not directly impact company operations or financial health.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The document does not specify any future actions, events, or milestones for the company, as it is solely a report of past insider transactions.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Officer Transactions, William Guyer, Common Stock, Share Sale, Biotechnology, Pharmaceuticals